Dr. Simpson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1653 W Congress Pkwy
# 1591
Chicago, IL 60612Phone+1 312-942-8114Fax+1 312-942-8975
Summary
- Dr. Mindy Simpson is a pediatric hematologist/oncologist at Rush University Medical Center in Chicago, IL. She is the medical director for the Rush Hemophilia and Thrombophilia Center and has been in practice 14 years. She specializes in pediatric coagulation disorders, such as bleeding disorders including hemophilia, von Willebrand Disease, platelet disorders, rare bleeding disorders as well as thrombophilia and blood clots. She is active in clinical trials and has participated as PI in numerous studies.
Education & Training
- University of ColoradoFellowship, Pediatric Hematology/Oncology, 2007 - 2010
- McGaw Medical Center of Northwestern UniversityResidency, Pediatrics, 2003 - 2006
- Lewis Katz School of Medicine at Temple UniversityClass of 2003
Certifications & Licensure
- IL State Medical License 2005 - 2026
- CO State Medical License 2007 - 2011
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Evaluation of the Duration of Therapy for Thrombosis in Children Start of enrollment: 2008 Mar 01
Publications & Presentations
PubMed
- Correction: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.Mark T Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore
Drugs in R&D. 2024-12-20 - 2 citationsDamoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.Mark T Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore
Drugs in R&D. 2024-09-01 - Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.Mark T Reding, Mindy Simpson, Jonathan Ducore, Pål Andrè Holme, Monika Maas Enriquez
Acta Haematologica. 2024-04-23
Press Mentions
- Study Suggests Another Look at Common Treatments for HemophiliaJune 13th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: